Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma.
PurposeThe purpose of the study was to investigate the outcomes of primary photodynamic therapy (PDT) for small pigmented posterior pole choroidal melanoma.Patients and methodsProspective interventional consecutive case series of 15 patients with small pigmented posterior pole choroidal melanoma, who were treated with three sessions of PDT and followed-up thereafter. Risk factors for failure were assessed and outcome measures at presentation were compared to those at last follow-up visit.ResultsTumor control was achieved in 12 (80%) patients in a median follow-up time of 15 months (mean 14, range 8-18). Three patients failed treatment, diagnosed in a median time of 5 months (mean 4, range 3-6), after first PDT. In all failed cases, lesions were 100% pigmented; de novo melanoma rather than transformed nevi and showed a radial growth pattern rather than increased thickness. All failed cases were subsequently successfully treated with radiotherapy. In this cohort, subretinal fluid (SRF) was significantly reduced (P<0.001), vision did not deteriorate (P=0.11) and even improved in patients with subfoveal SRF at presentation (P=0.018), tumor height significantly decreased (P=0.037) and no complications were recorded.ConclusionPrimary PDT was found to be a safe and efficient treatment modality for small pigmented posterior pole choroidal melanoma, achieving short-term tumor control in 80% of patients. PDT offers patients the opportunity to preserve vision by avoiding the retinopathy associated with conventional radiation treatments for choroidal melanoma. However, the long-term local control of these tumors remains uncertain.
Ocular Oncology Service, Moorfields Eye Hospital, London, UK.
I D
ID
Fabian
Ocular Oncology Service, Moorfields Eye Hospital, London, UK.|Department of Ophthalmology, University of Washington, Seattle, Washington, USA.
A W
AW
Stacey
Ocular Oncology Service, Moorfields Eye Hospital, London, UK.
V
V
Papastefanou
Ocular Oncology Service, Moorfields Eye Hospital, London, UK.
L
L
Al Harby
Ocular Oncology Service, Moorfields Eye Hospital, London, UK.
A K
AK
Arora
Ocular Oncology Service, Moorfields Eye Hospital, London, UK.|University College London Institute of Ophthalmology, London, UK.
M S
MS
Sagoo
Ocular Oncology Service, Moorfields Eye Hospital, London, UK.
V M L
VM
Cohen
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002830:Choroid Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome; D006113:United Kingdom; D000077362:Verteporfin; D014792:Visual Acuity
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin